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Mats Remberger,1,2 Malin Ackefors,3 Sofia Berglund,1,2 Ola Blennow,3 G€oran Dahll€of,4
Aldona Dlugosz,5 Karin Garming-Legert,4 Jens Gertow,1,2 Britt Gustafsson,6
Moustapha Hassan,7 Zuzana Hassan,1,7 Dan Hauzenberger,2 Hans H€agglund,8
Helen Karlsson,1,2 Lena Klingspor,9 Gunilla Kumlien,10 Katarina Le Blanc,2,8 Per Ljungman,8
Maciej Machaczka,8 Karl-Johan Malmberg,8 Hanns-Ulrich Marschall,5 Jonas Mattsson,1,2
Richard Olsson,1,2 Brigitta Omazic,1,2 Darius Sairafi,1,2 Marie Schaffer,2 Britt-Marie Svahn,1
Petter Svenberg,1,2 Lisa Swartling,3 Attila Szakos,11 Michael Uhlin,1,2 Mehmet Uzunel,1,2
Emma Watz,10 Annika Wernerson,11 Agneta Wikman,10 Ann-Charlotte Wikstr€om,12
Jacek Winiarski,6 Olle Ringden1,2Weanalyzed the outcomeof allogeneic hematopoietic stemcell transplantation (HSCT)over the past 2 decades.
Between 1992 and 2009, 953 patients were treatedwith HSCT, mainly for a hematologic malignancy. They were
dividedaccording to4different timeperiodsof treatment: 1992 to1995,1996 to2000, 2001 to2005, and2006 to
2009.Over theyears,many factors have changed considerably regardingpatient age, diagnosis, disease stage, type
of donor, stem cell source, genomic HLA typing, cell dose, type of conditioning, treatment of infections, use of
granulocyte-colony stimulating factor (G-CSF), use ofmesenchymal stemcells, useof cytotoxic T cells, andhome
care.Whenwe compared the last period (2006-2009) with earlier periods, we found slower neutrophil engraft-
ment, a higher incidence of acute graft-versus-host disease (aGVHD) of grades II-IV, and less chronic GVHD
(cGHVD). The incidence of relapse was unchanged over the 4 periods (22%-25%). Overall survival (OS) and
transplant-relatedmortality (TRM) improvedsignificantly in themore recent periods,with the best results during
the last period (2006-2009) and a 100-day TRM of 5.5%. This improvement was also apparent in a multivariate
analysis. When correcting for differences between the 4 groups, the hazard ratio for mortality in the last period
was 0.59 (95% confidence interval [CI]: 0.44-0.79; P\.001) and for TRM it was 0.63 (CI: 0.43-0.92; P5.02). This
study shows that the combinedefforts to improveoutcome afterHSCThavebeenveryeffective. Even thoughwe
now treat olderpatientswithmore advanceddisease and usemore alternativeHLAnonidentical donors,OS and
TRM have improved. The problem of relapse still has to be remedied. Thus, several different developments to-
gether have resulted in significantly lower TRM and improved survival after HSCTover the last few years.
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considerable changes in the transplantation procedure,
in treatment, and in patient selection. In particular, the
introduction in the early 1980s of a combination of
cyclosporine and methotrexate has significantly
reduced severe aGVHD and improved TRM [8,9].
The number of patients eligible for HSCT has
increased as a result of better treatments, and the
introduction of less toxic reduced-intensity condition-
ing (RIC) regimens has made it possible to admit
older patients and those with comorbidities [10-12].
During the late 1990s, the source of stem cells
shifted from bone marrow to peripheral blood stem
cells (PBSCs) [13-17]. Genomic tissue typing has
been employed to better match unrelated donors
[18,19]. The introduction of preemptive therapy
for cytomegalovirus (CMV) infection has improved
outcome and reduced the risk of fatal CMV disease
[20,21]. In our unit, the use of liposomal amphotericin
B after HSCT has significantly reduced the risk of
invasive fungal infection from 11% to around 5% [22].
Today, there is a large number of efficient antifungals
from which to choose. Other antiinfectious agents in-
clude new antibiotics and antiviral drugs such as acyclo-
vir, ganciclovir, and foscarnet [23]. By the introduction
of PCR methods to detect donor-recipient chimerism,
there has been improved diagnosis of graft failure [24].
Minimal residual disease detection of threatening re-
lapse has also been developed [25]. Donor lymphocyte
infusions (DLIs) are used for treatment of graft failure
and relapse [26,27]. Home care after HSCT has
reduced aGVHD and improved survival; this is now
routine practice in patients living within 2 hours’
driving distance of our hospital [28]. In more recent
years, mesenchymal stem cells have been introduced
by us and have been shown to have an effect in some pa-
tientswith severe aGVHDthat isotherwise refractory to
therapy [29]. A randomized study showed that the use of
ursodiol not only reduced liver toxicity, it also improved
survival [30]. Because of these improvements, patients
with higher age, with more resistant underlying disease,
and those with comorbidities have been accepted for
HSCT. The range of diagnoses in patients admitted
for HSCT has also changed over the years. Because
the proportion of patients admittedwithmore advanced
disease has increased with time, there was no apparent
improvement in patient survival for a long time. It was
therefore of interest to determine whether or not out-
come after HSCT has improved over the last 2 decades.PATIENTS AND METHODS
Patients
From January 1992 until December 2009, 1013 pa-
tients underwent HSCT at Karolinska University
Hospital, Huddinge, Sweden. Patients transplantedfor a solid tumor (n 5 60) were excluded, as this is
an experimental treatment with poor outcome [31].
In total, 953 patients were included in the study. Pa-
tient and donor characteristics are listed in Table 1.
There were 275 patients with acute myeloid leuke-
mia (AML), 176 with acute lymphoid leukemia (ALL),
161 with chronic myeloid leukemia (CML), 24 with
chronic lymphoid leukemia (CLL), 60 with lymphoma,
86 with myelodysplastic syndrome or myeloprolifera-
tive syndrome (MDS/MPS), 27 with multiple myeloma
(MM), and 6 with myelofibrosis (MF). One hundred
thirty-eight other patients had a nonmalignant disorder:
severe aplastic anemia (n 5 38), Fanconi anemia (n 5
13), inborn error of metabolism (n 5 80), or another
nonmalignant disease (n 5 7). The median age of all
patients was 34 years (0-69), and there were 545 males
and 408 females. There were 293 children under the
age of 18 years (31%). Almost one-half of the patients
(46%) had a malignancy beyond first complete
remission or first chronic phase (CR1/CP1), and were
considered to have high-risk disease.
The study was approved by the Ethics Committee
atHuddingeUniversityHospital. All patients included
in the study gave informed consent.
Donors
Donorswere anHLA-identical sibling in 406 cases,
at least an HLA-A, -B and -DRmatched unrelated do-
nor (MUD) in 419 cases, an allele-mismatched unre-
lated donor in 56 cases, or an antigen-mismatched
related or unrelated donor in 13 and 54 cases, respec-
tively. Five patients were transplanted from a syngeneic
twin. There were 531male and 410 female donors with
a median age of 35 years (range: 0-71).
HLATyping
All patients and donors were typed using PCR-SSP
high-resolution typing for both HLA class I and II an-
tigens (at the 4-digit level) [18,32-34].
Stem Cell Source
Bone marrow (BM) was given to 480 patients, and
429 patients received peripheral blood stem cells
(PBSCs) from a granulocyte-colony stimulating factor
(G-CSF) stimulated donor. In 44 cases, 1 (n 5 33) or 2
(n 5 11) cord blood units were used as grafts, mainly
for patients lacking an acceptable related or unrelated
donor. Median nucleated cell dose was 4.8  108/kg
(range: 0.03-81.3). The CD341 cell dose was known in
703 transplants and was median 6.3  106/kg (0.03-68).
Conditioning
Conventionalmyeloablative conditioningwas given
to 704 patients and consisted of cyclophosphamide (Cy)
at 60 mg/kg for 2 days in combination with 7.5-10
Gy single-fraction total body irradiation (sTBI)
Table 1. Characteristics of Patients Who Underwent Hematopoietic Stem Cell Transplantation from 1992 through 2009 at
Karolinska University Hospital, Grouped According to Time Period
Year of HSCT 1992-1995 1996-2000 2001-2005 2006-2009
Number 188 269 279 217
Diagnosis:
Acute leukemia 84 (45) 138 (51) 120 (43) 109 (50)
Chronic leukemia 53 (28) 69 (26) 43 (15) 19 (9)
MDS/MPS 10 (5) 14 (5) 30 (11) 32 (15)
Other hematol. malignancy 11 (6) 20 (7) 43 (15) 20 (9)
Nonmalignant disorders 30 (16) 28 (10) 43 (15) 37 (17)
High-risk disease 73 (39) 116 (43) 145 (52) 100 (46)
Age 28 (0.2-58) 32 (0-63) 35 (0-65) 39 (0.4-69)
Children (<18 years) 60 (32) 86 (32) 85 (30) 62 (29)
Sex (male/female) 118/70 145/124 161/118 121/96
Donor:
HLA-identical, related 106 (56) 112 (42) 106 (38) 87 (40)
MUD 72 (38) 126 (47) 126 (45) 95 (44)
Mismatched 10 (5) 31 (12) 47 (17) 35 (16)
Female to male 58 (31) 46 (17) 55 (20) 38 (18)
NC dose (108/kg) 2.3 (0.6-18.1) 4.1 (0.03-80) 8.6 (0.1-63.8) 9.8 (0.3-81)
Stem cell source:
BM/PBSCs/CB 183/5/0 158/111/0 92/170/17 47/143/27
Conditioning:
TBI-based MAC 143 (76) 175 (65) 54 (19) 43 (20)
Chemo-based MAC 42 (22) 77 (29) 100 (36) 70 (32)
RIC 3 (2) 17 (6) 125 (45) 104 (48)
ATG 87 (46) 179 (66) 211 (76) 157 (72)
GVHD prophylaxis:
CsA or MTX 4 4 7 0
CsA/tacrolimus + MTX 183 (97) 234 (87) 220 (79) 151 (70)
CsA + MMF 0 6 (2) 22 (8) 0
TcD 0 13 (5) 1 0
Other* 1 12 29 (10%) 66 (30)
G-CSF 44 (23%) 237 (88%) 50 (18%) 39 (18%)
MDS/MPS indicates myelodysplastic syndrome/myeloproliferative syndrome; High-risk, beyond CR1/CP1; HLA, human leukocyte antigen; MUD,
matched unrelated donor; NC dose, nucleated cell dose; BM, bone marrow; PBSCs, peripheral blood stem cells; CB, cord blood; TBI, total body irra-
diation; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; CsA,
cyclosporine A; MTX, methotrexate; MMF, mycofenolate mofetile; TcD, T cell depletion; G-CSF, granulocyte-colony stimulating factor.
Absolute numbers or medians are presented. Figures in parentheses show percentage or range.
*CsA + Prednisolone, Tacrolimus + Sirolimus.
1690 Biol Blood Marrow Transplant 17:1688-1697, 2011M. Remberger et al.(n 5 262), fractionated TBI (FTBI) at 3 Gy/day for 4
days (n 5 157), and busulphan (Bu) at 4 mg/kg/day
for 4 days (n5 270) [35]. Fifteen patients with severe
aplastic anemia (SAA) and a sibling donor received
Cy at 50 mg/m2 for 4 days.
Reduced-intensity conditioning (RIC) was given
to 249 patients and consisted of fludarabine (Flu) at
30 mg/m2 for 3 to 6 days in combination with Bu at
4 mg/kg/day for 2 days (n 5 125), FTBI at 3 Gy/day
for 2 days and Cy at 60 mg/kg/day for 2 days (n 5
49), Cy at 30 mg/kg/day for 2 days (n 5 34), treosul-
phan at 12 to 14 g/m2/day for 3 days (n 5 25), or
TBI (2 Gy) (n 5 16) [12,36,37].
All patients with an unrelated donor or a nonmalig-
nant disease received antithymocyte globuline (ATG,
Thymoglobulin, Genzyme, Cambridge, MA [n5 490]
or ATG-Fresenius, Fresenius, Gr€afelfing, Germany
[n 5 39]), alemzumab (Genzyme) (n 5 38), or
Orthoclone OKT-3 (Ortho Biothech, NJ) (n 5 66)
for 2 to 5 days during conditioning.
GVHD Prophylaxis
Immunosuppressive treatment consisted of cyclo-
sporine A (CsA) in combination with a short courseof methotrexate (MTX) (n 5 788), prednisolone (n
5 53), or mycophenolate mofetil (MMF) (n 5 28)
[8,9]. Fifty-one patients received tacrolimus combined
with sirolimus, and 10 received monotherapy with ei-
ther CsA or MTX. The patients with a syngeneic
twin donor received no immunosuppression, and 14
patients received a T cell-depleted graft [38].
During the first month, blood CsA levels were kept
at 100 ng/mL in patients withmalignancies when a sib-
ling donor was used and at 200 to 300 ng/mL when an
unrelated donorwas used and also in patients with non-
malignant disorders regardless of donor [39]. In the ab-
sence of GVHD, CsA was discontinued after 3 to 6
months for patients with malignancies and after 12 to
24 months for patients with nonmalignant disorders.
Supportive Care
Supportive care has been described in detail previ-
ously [40-42].
Diagnosis and Treatment of GVHD
Both aGVHD and cGVHDwere diagnosed on the
basis of clinical symptoms and/or biopsies (skin, liver,
Biol Blood Marrow Transplant 17:1688-1697, 2011 1691Improved Survival after Allogeneic HSCTgastrointestinal tract, or oral mucosa) according to
standard criteria [14]. The patients were treated for
grade-I aGVHD with prednisolone, starting at 2 mg/
kg/day, which was tapered after the initial response
[41]. In more severe cases, ATG, methylprednisolone,
MTX, psoralene and UV light (PUVA), or mesenchy-
mal stem cells were used [8,29]. First-line therapy for
cGVHD was CsA combined with corticosteroids
[43]. In nonresponders, additional immune suppres-
sion was given.
Definitions
Neutrophil engraftment was defined as the num-
ber of days after HSCT until absolute neutrophil
counts were .0.5  109/L for 2 consecutive days.
Platelet engraftment was defined as the first of 7 con-
secutive days with platelets .30  109/L without
transfusions.
Rejection was defined as .95% recipient chi-
merism in the CD33-positive cell population in
peripheral blood and/or bone marrow 4 weeks after
HSCT.
Statistics
The analysis was performed on May 15, 2010. OS
was calculated using the Kaplan-Meier method
and compared with the log-rank test [44]. TRM,
GVHD, graft failure, and relapse were estimated
using a nonparametric estimator of cumulative inci-
dence curves, taking competing events into consider-
ation. Univariate and multivariate risk factor analyses
for TRM and GVHD were performed using the pro-
portional subdistribution hazard regression model de-
veloped by Fine and Gray. Multivariate modeling for
OS and time-to-engraftment was performed using
Cox regression models (to estimate hazard ratios
[HRs]). Chronic GVHD was analyzed as a time-
dependent covariate in the Cox regression model. In
all multivariate analyses, HSCT during the years
2006 to 2009 were compared with HSCT during
1992 to 2005, and corrections were made for differ-
ences between the groups (age, donor, conditioning,
stem-cell source, nucleated-cell dose, G-CSF, and dis-
ease stage). AllP valueswere 2-tailed.Categoric param-
eters were compared using the chi-square test, and
continuous variables were compared using the Mann-
Whitney test. Analysis was performed using the cmprsk
software package (developed by Gray, June 2001),
Splus 6.2 software (Insightful, Seattle, WA) and Statis-
tica software (StatSoft, Tulsa, OK).RESULTS
The patients were divided into 4 groups depending
on year of transplantation. Group 1 consisted of
patients transplanted between 1992 and 1995 (n 5188), group 2 consisted of patients transplanted be-
tween 1996 and 2000 (n 5 269), group 3 of patients
transplanted 2001 to 2005 (n 5 279), and group 4 of
patients transplanted 2006 to 2009 (n 5 217). There
were considerable differences among these 4 groups
concerning age, type of donor, nucleated cell dose, di-
agnosis, the use of G-CSF, stem cell source, and type
of conditioning. This is illustrated in Table 1.
Engraftment
Graft failure occurred in 3.7%, 3.0%, 5.7%, and
6.0% of patients in the 4 groups (P5 .15 globally com-
paring all 4 periods).
Time to neutrophil engraftment changed consider-
ably over the years, as illustrated in Figure 1A. In the
corrected multivariate analysis, HSCT during 2006
to 2009 (HR 5 0.77, 95% CI: 0.66-0.91, P\ .001)
was found to be associated with slower neutrophil en-
graftment compared with HSCT during 1992 to
2005.Other factors associatedwith neutrophil engraft-
mentwere PBSCs (HR5 2.12,CI: 1.81-2.43,P\.001)
G-CSF (HR 5 1.26, CI: 1.10-1.45, P 5 .001), ATG
(HR 5 0.82, CI: 0.70-0.95, P \ .01), and CB graft
(HR 5 0.42, CI: 0.28-0.62, P\ .001).
Time to platelet engraftment (.30  109/L) was
shorter during the 2 last time periods compared with
earlier periods (P \ .001) (Figure 1B). However, in
the corrected multivariate analysis, platelet engraft-
ment in HSCT during 2006 to 2009 (HR 5 0.92,
CI: 0.78-1.09, P 5 .35) was not different from
HSCT during 1992 to 2005. Factors associated to
platelet engraftment were RIC (HR 5 1.23, CI:
1.03-1.46, P 5 0.02), PBSCs (HR 5 2.07, CI: 1.76-
2.43, P \ .001), CB graft (HR 5 0.52, CI:
0.37-0.74, P \ .001), and G-CSF (HR 5 0.62, CI:
0.54-0.72, P\ 0.001).
GVHD
The incidence of aGVHD of grades II-IV in-
creased from 13% (CI: 8%-18%) during 1992 to
1995 to 37% (30%-44%) during 2006 to 2009
(Figure 2A). In the corrected multivariate analysis,
we found that HSCT during 2006 to 2009 (HR 5
1.45, CI: 1.09-1.91, P 5 .01) was associated with
a higher incidence of aGVHD II-IV compared with
HSCT during 1992 to 2005. Other factors associated
with aGVHD of grades II-IV in multivariate analyses
were: MAC (HR 5 1.81, CI: 1.35-2.43, P \ .001),
PBSCs (HR 5 1.67, CI: 1.28-2.17, P \ .001), mis-
matched donor (HR 5 1.43, CI: 1.04-1.97, P 5
.027), and ABO blood group mismatch (HR 5 1.20,
CI: 1.05-1.38, P 5 .01).
The 1-year survival (95% CI) in patients with
aGVHD of grades II-IV was 42% (22%-62%), 52%
(42%-62%), 49% (39%-59%), and 73% (64%-82%)
in the 4 respective groups (P\ .001).
Figure 1. Box plot of time to neutrophil (A) and platelet (B) engraftment after allogeneic HSCTover 4 different time periods. Median, 25% to 75%
interquartile range and nonoutlier range. The P value refers to a global comparison of all 4 groups. ANC indicates absolute neutrophil count.
1692 Biol Blood Marrow Transplant 17:1688-1697, 2011M. Remberger et al.The incidence of cGVHD decreased from 47%
(95% CI: 40%-54%) to 30% (95% CI: 23%-37%)
over the entire study period (P\ .001 comparing all
4 periods) (Figure 2B). In the corrected multivariate
analysis, HSCT during 2006 to 2009 (HR 5 0.67,
CI: 0.49-0.92, P 5 .013) was associated with less
cGVHD compared with HSCT during 1992 to 2005.
Other factors associated with cGVHD were pa-
tient age (by decades) (HR 5 1.18, CI: 1.11-1.26, P
\ .001), HLA-identical related donor (HR 5 1.53,
CI: 1.21-1.93, P \ .001), TBI-based conditioning(HR 5 1.73, CI: 1.36-2.21, P \ .001), and G-CSF
(HR 5 1.39, CI: 1.09-1.76, P\ 0.01).TRM
TRM improved significantly over the entire study
period (P \ .001 comparing all 4 periods)
(Figure 3A). The 1-year TRM (95% CI) was 22%
(16%-28%), 22% (17%-27%), 19% (14%-24%), and
13% (9%-17%) in the 4 groups, respectively. In the
corrected multivariate analysis, HSCT during 2006
Figure 2. Cumulative incidence of aGVHDof grades II-IV (A) and cGVHD (B) after allogeneic HSCTover 4 different time periods. The P value refers to
a global comparison of all 4 groups.
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to be associated with lower TRM compared with
HSCT during 1992 to 2005.
Other factors associated withTRMwas patient age
(by decades) (HR 5 1.18, CI: 1.10-1.28, P\ .001),
acute leukemia (HR 5 0.65, CI: 0.50-0.86, P 5 .002),
HLA-identical related donor (HR 5 0.60, CI: 0.46-
0.78, P\ .001), RIC (HR 5 0.64, CI: 0.46-0.88, P 5
.007), and home care (HR5 0.55, 0.34-0.91, P5 .02).
OS
The 3-year OS (95%CI) improved over the years:
53% (46%-60%) during 1992 to 1995, 57% (51%-
63%) during 1996 to 2000, 60% (54%-66%) during
2001 to 2005, and 71% (65%-77%) during 2006 to2009 (P 5 .0015 comparing all 4 periods)
(Figure 3B). In the corrected multivariate analysis,
HSCT 2006 to 2009 was associated with less mortality
(HR 5 0.59, CI: 0.44-0.79, P\ .001) compared with
HSCT during 1992 to 2005.
Other factors associated with mortality were pa-
tient age (by decades) (HR 5 1.13, CI: 1.06-1.21, P
5 .003), malignant disease (HR 5 2.14, CI: 1.40-
3.29, P\ .001), unrelated or mismatched donor (HR
5 1.43, CI:1.17-1.73, P \ .001), high-risk disease
(HR 51.54, CI: 1.26-1.88, P \ .001), and low NC
dose (HR 5 1.02, CI: 1.00-1.03, P 5 .03).
A comparison of the various outcome variables
during the different time periods are shown in
Table 2.
Figure 3. Cumulative incidence of TRM (A) and probability of survival (B) 3 years after allogeneic HSCTover 4 different time periods. The P value refers
to a global comparison of all 4 groups.
1694 Biol Blood Marrow Transplant 17:1688-1697, 2011M. Remberger et al.Relapse
In patients with hematologic malignancies, the
incidence of relapse has not changed over the years:
It was approximately 25% in all 4 groups. When
corrected for differences among the 4 groups, no
difference in relapse incidence among the 4 groups
was seen.DISCUSSION
During the past, decades HSCT has changed con-
siderably with respect to stem cell source, conditioning,choice of donor, stem cell dose, prophylaxis, and treat-
ment of infections. These changes have been made to
improve morbidity and survival after HSCT. At the
same time, the indications for HSCT have changed
and as a consequence of using milder conditioning
(RIC), older patients and patients with more comor-
bidities have been accepted for HSCT [10-12]. This
may have affected the results in this cohort of
patients. Considering all these circumstances, has
the OS really improved? It was for this reason that
we decided to study the results from the last 2
decades and to determine whether there have been
significant improvements in outcome.
Table 2. Comparisons of Various Outcome Variables after HSCT during Four Different Time Periods
SCT years Mortality TRM aGVHD II-IV cGVHD Neutrophil Engraftment Platelet Engraftment
1992-1995 1.0 1.0 1.0 1.0 1.0 1.0
1996-2000 0.82 (0.57-1.16) 0.79 (0.48-1.28) 1.86 (1.03-3.35) 0.87 (0.4-1.39) 1.57 (1.25-1.96) 0.69 (0.55-0.87)
2001-2005 0.77 (0.57-1.06) 0.76 (0.46-1.23) 3.60 (2.04-6.35) 0.41 (0.24-0.69) 0.78 (0.60-1.03) 0.83 (0.63-1.08)
2006-2009 0.46 (0.31-0.70) 0.38 (0.22-0.66) 4.35 (2.37-7.99) 0.34 (0.16-0.70) 0.52 (0.38-0.71) 0.62 (0.46-0.83)
TRM indicates transplant-related mortality; aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD; SCT, stem cell transplantation; HSCT,
hematopoietic stem cell transplantation.
The earliest period (1992-1995) was used as a reference group and the analyses were corrected for differences between the groups. Hazard ratio (HR)
and 95% confidence interval (CI) are given for each comparison.
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patients, treated more patients beyond CR1, used
a wider range of donors, and given higher cell doses,
more PBSC and CB grafts, more RIC, and less TBI-
based conditioning. The use of G-CSF has also
changed over the years. Neutrophil engraftment was
slower during the last period (2006-2009) when cor-
rected for all differences in treatment during the years.
Initially, G-CSFwas used to speed up the engraftment.
However, when we found that it increased the risk of
aGVHD, it was discontinued [45,46].
The incidence of aGVHD of grades II-IV has in-
creased during recent years in multivariate analysis
corrected for differences between the groups. One
possibility is that we have been more aggressive in
making the diagnosis of GVHD, for example, by en-
doscopy. Other changes in practice that were not cor-
rected for in the multivariate analysis may have
affected the incidence of GVHD. In most studies,
aGVHD II-IV has been associated with an inferior
survival [47]. However, survival in patients with
moderate-to-severe GVHD has improved signifi-
cantly in recent years. The use of mesenchymal stem
cells may improve short-term survival in patients
with GVHD of grades III-IV [29]. Prophylaxis using
new antifungals in patients with moderate and severe
aGVHD may have improved their survival in the last
few years.
After correcting for differences between the
groups, the incidence of cGVHD over the years has
apparently decreased. The fact that the incidence of
cGVHD has decreased in recent years is surprising,
because our aim has been to induce cGVHD in pa-
tients with hematologic malignancies to better induce
a graft-versus-leukemia effect [39]. One factor in more
recent years that might have counterbalanced this
effect is that we use more CB, which reduces the risk
of cGVHD.
TRM decreased significantly during the last time
period. Several factors may have contributed to the im-
proved TRM, although not detected in the multivari-
ate analysis. One such factor is the introduction of
targeted Bu levels, which reduces toxicity. Although
Epstein-Barr virus-associated lymphoma is a relatively
rare cause of death after HSCT, it can now be treatedwith B cell antibodies and EBV-specific cytotoxic T
cells; and with such treatment, most patients survive
[48,49]. Hemorrhagic cystitis (HC) is another rare
complication that has been successfully treated in
a few patients using mesenchymal stem cells [50]. Al-
though only relatively few patients will be helped by
each of these new interventions, taken together they
may improve TRM, as seen in the last period. In keep-
ing with this, after correcting for all differences be-
tween groups, we found improved TRM in the last
period.
Detection and treatment of relapse has changed
over the years. The introduction of chimerism analysis
in leukemia-specific cell lineages and monitoring of
CML and Ph11 ALL patients with BCR/ABL PCR
have made it possible to detect and treat relapse at an
earlier stage. Early treatment of relapse with DLI
may improve response and survival [25]. Despite the
wider use of DLI for correction of chimerism, the
probability of relapse has not decreased in recent years.
The reason for this may be that cGVHD has decreased
and it has a major influence on relapse in patients with
leukemia [51-53]. Other possible reasons are fewer
patients transplanted for CML in recent years,
because this disease is very sensitive to DLI, and
more patients transplanted for high-risk AML and
MDS.
Most important, OS survival has improved signifi-
cantly during recent years, even though we now trans-
plant older patients, treat more high-risk disease, and
use more alternative donors—all factors that were as-
sociated with inferior survival in the multivariate anal-
ysis. This may have been balanced by a higher
nucleated cell dose during the last time period. How-
ever, survival improved during the last period, even
when corrected for all differences between the groups.
This indicates that other factors were associated with
the improved survival. Such factors may be better diag-
nosis, prophylaxis, and treatment of infections; im-
proved care of the patients; and a better
understanding of the importance of nutritional status
[54]. Furthermore, all improvements that have collec-
tively reduced TRM have also improved survival be-
cause the risk of relapse was unchanged. In addition
to this, accumulated experience locally and an
1696 Biol Blood Marrow Transplant 17:1688-1697, 2011M. Remberger et al.increased level of clinical knowledge and competence
among our staff have also contributed. Moreover, inte-
gration of our own research in the field as well as input
from other units in the Centre for International Blood
and Marrow Transplant Research and the European
Group for Blood and Marrow Transplantation have
helped us to treat HSCT in the best way possible.
Thus, several factors together have most likely con-
tributed to the improved overall survival. Our results
are consistent with 2 very recently published papers
addressing basically the same issue [55,56].
We conclude that TRM and overall survival have
improved in recent years. The reasons for this might
be improved diagnosis, prophylaxis, and treatment of
infections; improved treatment of GVHD; improved
care of the patients; and a general increase in the
knowledge and skill of the staff.ACKNOWLEDGMENTS
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